AU2004241830B9 - Antitumor agent and process for producing the same - Google Patents

Antitumor agent and process for producing the same Download PDF

Info

Publication number
AU2004241830B9
AU2004241830B9 AU2004241830A AU2004241830A AU2004241830B9 AU 2004241830 B9 AU2004241830 B9 AU 2004241830B9 AU 2004241830 A AU2004241830 A AU 2004241830A AU 2004241830 A AU2004241830 A AU 2004241830A AU 2004241830 B9 AU2004241830 B9 AU 2004241830B9
Authority
AU
Australia
Prior art keywords
sma
antitumor agent
pirarubicin
polymeric
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2004241830A
Other languages
English (en)
Other versions
AU2004241830B2 (en
AU2004241830A1 (en
Inventor
Khaled Greish
Hiroshi Maeda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2004241830A1 publication Critical patent/AU2004241830A1/en
Application granted granted Critical
Publication of AU2004241830B2 publication Critical patent/AU2004241830B2/en
Publication of AU2004241830B9 publication Critical patent/AU2004241830B9/en
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2004241830A 2003-05-26 2004-02-02 Antitumor agent and process for producing the same Expired AU2004241830B9 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003147852 2003-05-26
JP2003-147852 2003-05-26
PCT/JP2004/000993 WO2004103409A1 (ja) 2003-05-26 2004-02-02 抗腫瘍剤及びその製造方法

Publications (3)

Publication Number Publication Date
AU2004241830A1 AU2004241830A1 (en) 2004-12-02
AU2004241830B2 AU2004241830B2 (en) 2010-02-25
AU2004241830B9 true AU2004241830B9 (en) 2010-04-22

Family

ID=33475378

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004241830A Expired AU2004241830B9 (en) 2003-05-26 2004-02-02 Antitumor agent and process for producing the same

Country Status (11)

Country Link
US (1) US7682630B2 (enExample)
EP (1) EP1627645B1 (enExample)
JP (1) JP4669393B2 (enExample)
CN (1) CN1697663A (enExample)
AU (1) AU2004241830B9 (enExample)
CA (1) CA2489259C (enExample)
ES (1) ES2642179T3 (enExample)
HU (1) HUE035003T2 (enExample)
PT (1) PT1627645T (enExample)
TW (1) TW200505414A (enExample)
WO (1) WO2004103409A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8128959B2 (en) 2005-04-18 2012-03-06 Hiroshi Maeda Polymeric pharmaceutical agent for treatment of cancer and method for production of the same
ES2357325T3 (es) * 2005-09-12 2011-04-25 Yogesh Bendale. N Platino biológico novedoso, procedimiento de preparación, procedimiento de administración para tratamiento antitumoral.
FR2922452B1 (fr) * 2007-10-19 2010-01-22 Coatex Sas Formulations de composes organoplatiniques en presence de polymeres associatifs, produits obtenus et leurs utilisations
JP2010013411A (ja) * 2008-07-05 2010-01-21 Hiroshi Maeda 抗炎症剤
DK2774625T3 (en) 2011-09-05 2017-06-12 Hiroshi Maeda POLYMER TYPE FLUORESCING MOLECULE PROBE
JP6083738B2 (ja) * 2013-03-06 2017-02-22 公立大学法人大阪市立大学 ホウ素中性子捕捉療法用組成物およびその製造方法
CN105764491A (zh) 2013-12-09 2016-07-13 度瑞公司 药物活性剂复合物、聚合物复合物，以及包括其的组合物和方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0087957A1 (en) * 1982-02-27 1983-09-07 Kuraray Co., Ltd. Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component
WO2001052893A1 (en) * 2000-01-21 2001-07-26 Theryte Ltd Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58149903A (ja) 1982-02-27 1983-09-06 Kuraray Co Ltd ネオカルチノスタチン複合体の製造法
JPS6075499A (ja) 1983-08-08 1985-04-27 Kuraray Co Ltd ネオカルチノスタチン誘導体及びその製造法
JP2556865B2 (ja) * 1986-09-19 1996-11-27 山之内製薬株式会社 ネオカルチノスタチン誘導体の非注射投与用組成物
US5281710A (en) * 1990-08-01 1994-01-25 The Scripps Research Institute Dynemicin analogs: synthesis, methods of preparation and use
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0087957A1 (en) * 1982-02-27 1983-09-07 Kuraray Co., Ltd. Neocarzinostatin complexes, a method for producing the same, and an antitumor agent containing said complexes as an active component
WO2001052893A1 (en) * 2000-01-21 2001-07-26 Theryte Ltd Composition consisting of an active ingredient and a therapeutically active delivery system, especially in the treatment of angiogenesis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRESIH KHALED et al; Drug Delivery System, (10 May 2003), Vol 18, No 3, page 254 *
ZHUTING W et al; Chinese Journal of Polymer Science (1986) Vol 4, No 4, pgs 359-369 *

Also Published As

Publication number Publication date
EP1627645A1 (en) 2006-02-22
TWI332834B (enExample) 2010-11-11
PT1627645T (pt) 2017-11-23
WO2004103409A1 (ja) 2004-12-02
CA2489259A1 (en) 2004-12-02
AU2004241830B2 (en) 2010-02-25
CN1697663A (zh) 2005-11-16
US7682630B2 (en) 2010-03-23
ES2642179T3 (es) 2017-11-15
EP1627645A4 (en) 2008-12-24
CA2489259C (en) 2011-08-30
US20050208136A1 (en) 2005-09-22
HUE035003T2 (en) 2018-05-02
EP1627645B1 (en) 2017-08-23
TW200505414A (en) 2005-02-16
AU2004241830A1 (en) 2004-12-02
JPWO2004103409A1 (ja) 2006-07-20
JP4669393B2 (ja) 2011-04-13

Similar Documents

Publication Publication Date Title
Li et al. pH-sensitive polymeric micelles for targeted delivery to inflamed joints
US20020041898A1 (en) Novel targeted delivery systems for bioactive agents
Nakayama et al. Multi-targeting cancer chemotherapy using temperature-responsive drug carrier systems
JP4514455B2 (ja) Ｔｎｐ−４７０ポリマー複合体及びその使用
CN102475891A (zh) 具有pH响应性的聚乙二醇-抗癌药键合物及其合成方法和用途
JP2003531930A (ja) 両親媒性大環状誘導体およびそれらの類似体
CA2468548A1 (en) Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
JP2011524446A (ja) ポリグリコールで修飾されたキトサンオリゴ糖脂肪酸グラフト体、その調製方法およびその使用
JP2000509394A (ja) 細胞膜を横切って物質を輸送するためのポリペプチド結合体
CN105476975B (zh) 主动靶向型抗脑肿瘤药物及其制备方法
Zhang et al. Zwitterionic targeting doxorubicin-loaded micelles assembled by amphiphilic dendrimers with enhanced antitumor performance
AU2004241830B9 (en) Antitumor agent and process for producing the same
Maeda et al. Improvement of pharmacological properties of protein-drugs by tailoring with synthetic polymers
CN108126210B (zh) 一种单靶向还原响应囊泡纳米药物在制备脑肿瘤治疗药物中的应用
CN104367556B (zh) 一种能提供一氧化氮的透明质酸硝酸酯去氧胆酸聚合物胶束的制备方法及其应用
CN114159578A (zh) 一种基于诊疗分子共组装的血栓靶向纳米探针的制备及应用
JP4522452B2 (ja) 高分子型癌治療用医薬およびその製造方法
Zhang et al. The potential of poly [N-(2-hydroxypropyl) methacrylamide] via reversible addition-fragmentation chain transfer polymerization as safe nanocarrier
Li et al. Research Progress on the nano-delivery systems of antitumor drugs
CN117122696B (zh) 一种血栓靶向自增敏杂化纳米组装体及其制备方法与应用
WO2010143218A1 (en) Polymeric conjugates of phospholipids
Li et al. T cell/Macrophage Dual-Targeting Biomimetic Triptolide Self-Assembly Nanodrugs For Rheumatoid Arthritis Therapy by Inflammatory Microenvironment Remodeling
Martins et al. Intelligent delivery of antitumor drugs mediated by polymeric nanomicelles: a review
CN115068624A (zh) 一种肽类树形分子载药体系及其制备方法和应用
CN114404610A (zh) 透明质酸-香叶醇聚合物前药多生物响应的给药系统HSSG NPs及其制备方法和应用

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired